Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · Real-Time Price · USD
78.24
+1.63 (2.13%)
Aug 13, 2025, 4:00 PM - Market closed
Nuvalent Employees
Nuvalent had 142 employees as of December 31, 2024. The number of employees increased by 50 or 54.35% compared to the previous year.
Employees
142
Change (1Y)
50
Growth (1Y)
54.35%
Revenue / Employee
n/a
Profits / Employee
-$2,417,908
Market Cap
5.64B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 142 | 50 | 54.35% |
| Dec 31, 2023 | 92 | 30 | 48.39% |
| Dec 31, 2022 | 62 | 22 | 55.00% |
| Dec 31, 2021 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NUVL News
- 14 hours ago - Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium - PRNewsWire
- 6 days ago - Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results - PRNewsWire
- 23 days ago - Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC - PRNewsWire
- 7 weeks ago - Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - PRNewsWire
- 7 weeks ago - Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib - PRNewsWire
- 2 months ago - Nuvalent Appoints Christy Oliger to Board of Directors - PRNewsWire
- 3 months ago - Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results - PRNewsWire
- 3 months ago - Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PRNewsWire